Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality. This
review compared two of the main treatment alternatives: quinolone or macrolide …

Objective The best treatment option for hospitalized patients with community-acquired
pneumonia (CAP) has not been defined. The effectiveness of β-lactam/fluoroquinolone …

Introduction Guidelines recommend respiratory fluoroquinolone monotherapy or β-lactam
plus macrolide combination therapy as first-line options for hospitalized adults with mild to …

The relative efficacy, safety and ecological implications of macrolides vs. quinolones in the
treatment of community-acquired pneumonia (CAP) are debatable. We performed a …

Scope To study the factors associated with mortality in hospitalized patients with community‐
acquired pneumonia treated with monotherapy or combination therapy. Methods PubMed …

OBJECTIVE: To determine the role of newer fluoroquinolones (FQs) for adults with
community-acquired pneumonia (CAP) whose level of illness allows treatment with an oral …

Background The majority of community-acquired pneumonia (CAP) patients (about 80%)
will be treated as outpatients, because therapy with a single agent will work. For the …

The aim of this study was to compare more conclusively the efficacy and safety of
moxifloxacin, a new respiratory fluoroquinolone antibiotic, with β-lactam-based standard …

Background: For years, monotherapy with a β-lactam antibiotic (penicillin, amoxicillin or
second-generation cephalosporin) was recommended as empirical therapy for patients with …

Background: We investigated whether the use of respiratory fluoroquinolones was
associated with better clinical outcomes compared with the use of macrolides and β-lactams …